{"summary":"I have 20+ years of experience in cancer biology, metastasis, and developmental pathways, including line management, networking of academic collaborators and consultants, and project leadership experience. I have worked in all preclinical stages of the drug discovery process, early clinical and translational development of oncology therapeutics in different tumor types (breast, GI, CNS, Lung, and AML). I directly contributed to in vitro and in vivo target\/mechanism validation and PoC steps. I have competence in the development of Wnt and Smo antagonists, PI3K inhibitors, tyrosine kinase inhibitors, and antibody-drug conjugates. I am an author\/co-author of several publications in peer-reviewed journals and an inventor on two international patents. ","lastName":"Salerno","objectUrn":"urn:li:member:28867920","geoRegion":"Utrecht, Utrecht, Netherlands","fullName":"Massimiliano Salerno","firstName":"Massimiliano","currentPositions":[{"companyName":"Merus N.V.","title":"Director","tenureAtCompany":{"numYears":2,"numMonths":5},"companyUrnResolutionResult":{"employeeCountRange":"201-500","headquarters":{"geographicArea":"Utrecht","country":"Netherlands","city":"Utrecht","postalCode":"3584 CM","line1":"Yalelaan 62"},"website":"http:\/\/www.merus.nl","flagshipCompanyUrl":"https:\/\/www.linkedin.com\/company\/merus\/","industry":"Biotechnology Research"},"startedOn":{"year":2022},"companyUrn":"urn:li:fs_salesCompany:1255335"}],"entityUrn":"urn:li:fs_salesProfile:(ACwAAAG4fVABoS0ysqQ7ptdB943UeClkvFUfiS0,NAME_SEARCH,a7Rb)","projects":[],"contactInfo":{},"industry":"Pharmaceutical Manufacturing","educations":[{"degree":"Master of Science - MS","schoolUrn":"urn:li:fs_salesSchool:9333","eduId":121510951,"school":"urn:li:fs_salesSchool:9333","fieldsOfStudy":["Biology\/Biological Sciences, General"],"schoolName":"Sapienza Universit\u00e0 di Roma"},{"degree":"Specialty School","schoolUrn":"urn:li:fs_salesSchool:9333","eduId":121510985,"school":"urn:li:fs_salesSchool:9333","fieldsOfStudy":["Medicine Genetics"],"schoolName":"Sapienza Universit\u00e0 di Roma"}],"skills":[{"numOfEndorsement":37,"name":"Molecular Biology"},{"numOfEndorsement":33,"name":"Cell"},{"numOfEndorsement":26,"name":"Drug Discovery"},{"numOfEndorsement":20,"name":"Assay Development"},{"numOfEndorsement":20,"name":"Cell Biology"},{"numOfEndorsement":18,"name":"Biochemistry"},{"numOfEndorsement":15,"name":"Biotechnology"},{"numOfEndorsement":17,"name":"Oncology"},{"numOfEndorsement":14,"name":"Cell Culture"},{"numOfEndorsement":13,"name":"Pharmacology"},{"numOfEndorsement":10,"name":"Genetics"},{"numOfEndorsement":10,"name":"Cancer"},{"numOfEndorsement":8,"name":"Cancer Research"},{"numOfEndorsement":6,"name":"Genomics"},{"numOfEndorsement":6,"name":"Biomarkers"},{"numOfEndorsement":6,"name":"Translational Research"},{"numOfEndorsement":6,"name":"Animal Models"},{"numOfEndorsement":3,"name":"Project Leadership"},{"numOfEndorsement":2,"name":"Matrix Management"},{"numOfEndorsement":9,"name":"In Vitro"}],"numOfConnections":750,"patents":[{"inventors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAG4fVABoS0ysqQ7ptdB943UeClkvFUfiS0,NAME_SEARCH,a7Rb)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAKt4q0B0jmhK_NMohiZwqWrgGpvOfMYDP4,NAME_SEARCH,p80M)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAVdoNwBcm-gbH43Dnjbewvssclyf9ahA1c,NAME_SEARCH,82-K)"}],"description":"The present invention relates to known and novel compounds of formula (I) as herein described and pharmaceutical compositions thereof. The compounds of formula (I) have inhibitory effect on the Wnt pathway and are therefore useful in the preparation of a medicament, in particular for the treatment of cancer.","title":"WNT PATHWAY ANTAGONISTS","issuer":"eu","issuedOn":{"month":6,"day":10,"year":2010}},{"inventors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAG4fVABoS0ysqQ7ptdB943UeClkvFUfiS0,NAME_SEARCH,a7Rb)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAKt4q0B0jmhK_NMohiZwqWrgGpvOfMYDP4,NAME_SEARCH,p80M)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAVdoNwBcm-gbH43Dnjbewvssclyf9ahA1c,NAME_SEARCH,82-K)"}],"description":"The present invention relates to novel compounds of formula (I) : as herein described and pharmaceutical compositions thereof. The compounds of formula (I) have inhibitory effect on the Wnt pathway and are therefore useful in the preparation of a medicament, in particular for the treatment of cancer.","title":"WNT PATHWAY ANTAGONISTS","issuer":"eu","issuedOn":{"month":3,"day":23,"year":2012}}],"headline":"Man of Science                                                                                                                                                                    \n\n\n\n\n\n\n\n","courses":[{"name":"Il Ruolo Strategico del Medical Science Liaison durante il Ciclo di Vita del Prodotto","number":"Life Science Academy"},{"name":"Project Management","number":"Franklin Covey"},{"name":"Project Management Essentials","number":"Franklin Covey"},{"name":"Public Speaking"},{"name":"Speaking about Science","number":"Premiere Public Speaking"},{"name":"Rodent Workshop","number":"Office of Animal Care"},{"name":"Leadership Development Program","number":"TIAS"}],"certifications":[],"memberBadges":{"premium":false,"openLink":false,"jobSeeker":false},"flagshipProfileUrl":"https:\/\/www.linkedin.com\/in\/massimiliano-salerno-b808019","organizations":[{"name":"American Association for Cancer Research","position":"Active Member","startedOn":{"month":1,"year":2001}},{"name":"Journal of Translational Medicine","description":"In your role as Associate Editor, you play a pivotal role in assessing manuscripts in your field of expertise, guiding them through the peer review process, and ensuring they adhere to the ethos, editorial standards, policies, and scope of the journal.","position":"Associate Editor","startedOn":{"month":10,"year":2020}}],"location":"Utrecht, Utrecht, Netherlands","publications":[{"name":"Identification of 2-aminopyrimidine derivatives as inhibitors of the canonical Wnt signaling pathway.","publishedOn":{"month":7,"day":17,"year":2015},"publisher":"Bioorg Med Chem","url":"http:\/\/26233797","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAABj1gcIB0xr1ZK_W3vG9nmB8CIt9KaLxDO4,NAME_SEARCH,ZZHo)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAFHrMUBHSSbBVrEQ4YSG74m7fSywl9p1Sc,NAME_SEARCH,e_C1)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAG4fVABoS0ysqQ7ptdB943UeClkvFUfiS0,NAME_SEARCH,a7Rb)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAKt4q0B0jmhK_NMohiZwqWrgGpvOfMYDP4,NAME_SEARCH,p80M)"}]},{"name":"Structure\u2013activity relationship and properties optimization of a series of Quinazoline-2,4-diones as inhibitors of the canonical Wnt pathway","publishedOn":{"year":2015},"publisher":"European Journal of Medicinal Chemistry","url":"http:\/\/10.1016\/j.ejmech.2015.03.055","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAG4fVABoS0ysqQ7ptdB943UeClkvFUfiS0,NAME_SEARCH,a7Rb)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAczQi0BH49KXJbZZDSBPZHoiN18WF0TBMs,NAME_SEARCH,-DYk)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAjEHwoBhxslgR1jowxtrvT44fgupjiDHa0,NAME_SEARCH,Mmz9)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAADD75cBq8pLGV-dwdeQwWF0On_Z_NDJup4,NAME_SEARCH,wnXC)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAArN4pUB6-JLegg1NjeBJ5h4QjgfZfn5Y-g,NAME_SEARCH,DZt5)"}]},{"name":"Human Sarcoma growth Is sensitive to small-molecule mediated AXIN stabilization","publishedOn":{"month":5,"day":19,"year":2014},"publisher":"PLoS One","url":"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/24842792","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAADD75cBq8pLGV-dwdeQwWF0On_Z_NDJup4,NAME_SEARCH,wnXC)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAArN4pUB6-JLegg1NjeBJ5h4QjgfZfn5Y-g,NAME_SEARCH,DZt5)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAjEHwoBhxslgR1jowxtrvT44fgupjiDHa0,NAME_SEARCH,Mmz9)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAczQi0BH49KXJbZZDSBPZHoiN18WF0TBMs,NAME_SEARCH,-DYk)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAHDvmgBsKMB0dArvUIVHEMlHpMMx1ScKpU,NAME_SEARCH,SjYa)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAKt4q0B0jmhK_NMohiZwqWrgGpvOfMYDP4,NAME_SEARCH,p80M)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAABev5NABXV344MkuDvmwSFg8rWkFkopL33A,NAME_SEARCH,45uw)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAG4fVABoS0ysqQ7ptdB943UeClkvFUfiS0,NAME_SEARCH,a7Rb)"}]},{"name":"Identification and characterization of a small molecule inhibitor of Wnt signaling in glioblastoma cells","publishedOn":{"month":4,"day":25,"year":2013},"publisher":"Molecular Cancer Therapeutics","url":"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23619303","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAjEHwoBhxslgR1jowxtrvT44fgupjiDHa0,NAME_SEARCH,Mmz9)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAArN4pUB6-JLegg1NjeBJ5h4QjgfZfn5Y-g,NAME_SEARCH,DZt5)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAczQi0BH49KXJbZZDSBPZHoiN18WF0TBMs,NAME_SEARCH,-DYk)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAArUYicB2w6q_8N9VLZs7v7jvrvgHkHHV8I,NAME_SEARCH,5iIk)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAANyZtQBPw4XFD3MtAwbw1YZY5y277uhmhs,NAME_SEARCH,9b9b)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAADx3xUBp22bUh7usiNOr2AA_qeUdXpcZQw,NAME_SEARCH,MxI6)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAKt4q0B0jmhK_NMohiZwqWrgGpvOfMYDP4,NAME_SEARCH,p80M)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAFHrMUBHSSbBVrEQ4YSG74m7fSywl9p1Sc,NAME_SEARCH,e_C1)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAG4fVABoS0ysqQ7ptdB943UeClkvFUfiS0,NAME_SEARCH,a7Rb)"}]},{"name":"How to achieve confidence in drug discovery and development: managing risk (from a reductionist to a holistic approach)","publishedOn":{"year":2009},"publisher":"Chem Med Chem","url":"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/19434656","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAG4fVABoS0ysqQ7ptdB943UeClkvFUfiS0,NAME_SEARCH,a7Rb)"}]},{"name":"Nm23-H1 metastasis suppressor expression level influences the binding properties, stability, and function of the kinase suppressor of Ras1 (KSR1) Erk scaffold in breast carcinoma cells","publishedOn":{"year":2005},"publisher":"Mol Cell Biol","url":"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/15684389","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAG4fVABoS0ysqQ7ptdB943UeClkvFUfiS0,NAME_SEARCH,a7Rb)"}]},{"name":"Medroxyprogesterone acetate elevation of Nm23-H1 metastasis suppressor expression in hormone receptor-negative breast cancer","publishedOn":{"year":2005},"publisher":"J Natl Cancer Inst","url":"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/15870434","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAG4fVABoS0ysqQ7ptdB943UeClkvFUfiS0,NAME_SEARCH,a7Rb)"}]},{"name":"Inhibition of signal transduction by the nm23 metastasis suppressor: possible mechanisms","publishedOn":{"year":2003},"publisher":"Clin Exp Metastasis","url":"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/12650601","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAG4fVABoS0ysqQ7ptdB943UeClkvFUfiS0,NAME_SEARCH,a7Rb)"}]},{"name":"Histidine kinases and histidine phosphorylated proteins in mammalian cell biology, signal transduction and cancer.","publishedOn":{"month":2,"day":10,"year":2003},"publisher":"Cancer Letters","url":"http:\/\/12536071","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAG4fVABoS0ysqQ7ptdB943UeClkvFUfiS0,NAME_SEARCH,a7Rb)"}]},{"name":"Metastasis suppressor genes: basic biology and potential clinical use.","publishedOn":{"month":4,"day":4,"year":2003},"publisher":"Clinical Breast Cancer","url":"http:\/\/12744759","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAG4fVABoS0ysqQ7ptdB943UeClkvFUfiS0,NAME_SEARCH,a7Rb)"}]},{"name":"Basic and translational advances in cancer metastasis: Nm23.","publishedOn":{"month":2,"day":10,"year":2003},"publisher":"Journal of Bioenergetics and Biomembranes","url":"http:\/\/12848344","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAG4fVABoS0ysqQ7ptdB943UeClkvFUfiS0,NAME_SEARCH,a7Rb)"}]},{"name":"Nm23-H1 metastasis suppressor phosphorylation of kinase suppressor of Ras via a histidine protein kinase pathway","publishedOn":{"year":2002},"publisher":"J Biol Chem","url":"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/12105213","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAG4fVABoS0ysqQ7ptdB943UeClkvFUfiS0,NAME_SEARCH,a7Rb)"}]},{"name":"Interactions with single-stranded and double-stranded DNA-binding factors and alternative promoter conformation upon transcriptional activation of the Htf9-a\/RanBP1 and Htf9-c genes.","publishedOn":{"year":1998},"publisher":"J Biol Chem","url":"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/9417108","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAG4fVABoS0ysqQ7ptdB943UeClkvFUfiS0,NAME_SEARCH,a7Rb)"}]},{"name":"MEN1309\/OBT076, a first-in-class Antibody-drug Conjugate (ADC) targeting CD205 in solid tumors.","publishedOn":{"month":6,"day":21,"year":2019},"publisher":"Molecular Cancer Therapeutics","url":"https:\/\/www.ncbi.nlm.nih.gov\/m\/pubmed\/31227646\/","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAG4fVABoS0ysqQ7ptdB943UeClkvFUfiS0,NAME_SEARCH,a7Rb)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAABeqnNABTbn9JsvjNhjEH6ZDT5vq5zeSvUQ,NAME_SEARCH,ZzWk)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAABe_aPwBQUjkuPu7FYkBf9dOj6Irwolkv0U,NAME_SEARCH,hzSU)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAGLHqMBeaKDAFoDKWAiKDMHR4ExMn6cr0U,NAME_SEARCH,vsCg)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAABcjqQwBS4tXnB8AL5TG3n3VKlzzrtO2VeM,NAME_SEARCH,b7jM)"}]},{"name":"An Ig transmembrane domain motif improves the function of TCRs transduced in human T cells: implications for immunotherapy","publishedOn":{"month":5,"year":2019},"description":"","publisher":"J Immunotherapy","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAG4fVABoS0ysqQ7ptdB943UeClkvFUfiS0,NAME_SEARCH,a7Rb)"},{"entityUrn":"urn:li:fs_salesProfile:(ACwAABj8egIBoRMAONKP6EGspvLCpzFlZ6wr8UY,NAME_SEARCH,lGJP)"}]},{"name":"Antitumor activity of the PI3K \u03b4-sparing inhibitor MEN1611 in PIK3CA mutated, trastuzumab-resistant HER2 + breast cancer","publishedOn":{"month":5,"day":1,"year":2023},"publisher":"Breast Cancer Res Treat . 2023 May;199(1):13-23.","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAG4fVABoS0ysqQ7ptdB943UeClkvFUfiS0,NAME_SEARCH,a7Rb)"}]},{"name":"The activity of a PI3K \u03b4-sparing inhibitor, MEN1611, in non-small cell lung cancer cells with constitutive activation of the PI3K\/AKT\/mTOR pathway","publishedOn":{"month":11,"day":14,"year":2023},"publisher":"Frontiers in Oncology","url":"https:\/\/doi.org\/10.3389\/fonc.2023.1283951","authors":[{"entityUrn":"urn:li:fs_salesProfile:(ACwAAAG4fVABoS0ysqQ7ptdB943UeClkvFUfiS0,NAME_SEARCH,a7Rb)"}]}],"positions":null,"posts":[{"createdAt":1716899880000,"insightId":"47c0c123-ad0f-48ad-86c9-f895b46024e4","activityUnion":{"postActivity":{"contentSummaryUnion":{"ingestedContentSummary":{"image":{"attributes":[{"originalImageUrl":"https:\/\/media.licdn.com\/dms\/image\/sync\/D5627AQFjaYvX-apgTg\/articleshare-shrink_800\/0\/1716894488621?e=1717977600&v=beta&t=WXpM532jNcn53MASjUM1dk8ABT7INqEs534L7DY2_OA","sourceType":"URL","imageUrl":"https:\/\/media.licdn.com\/dms\/image\/sync\/D5627AQFjaYvX-apgTg\/articleshare-shrink_800\/0\/1716894488621?e=1717977600&v=beta&t=WXpM532jNcn53MASjUM1dk8ABT7INqEs534L7DY2_OA"}]},"description":"The Investor Relations website contains information about Merus's business for stockholders, potential investors, and financial analysts.","resolvedUrl":"https:\/\/ir.merus.nl\/news-releases\/news-release-details\/merus-petosemtamab-combination-pembrolizumab-interim-data","title":"Merus\u2019 Petosemtamab in Combination with Pembrolizumab Interim Data Demonstrates Robust Response Rate and Favorable Safety Profile in 1L r\/m HNSCC - Merus"}},"socialMetadata":{"reactionTypeCounts":[{"type":"LIKE","count":14},{"type":"PRAISE","count":1},{"type":"EMPATHY","count":2}],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:activity:7201200167750901761","threadUrn":"urn:li:activity:7201200167750901761","reactionsCount":17,"commentsCount":0,"canComment":true},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:share:7201200167172141057","message":{"attributes":[],"text":""},"entityUrn":"urn:li:share:7201200167172141057"}}},{"createdAt":1717166640000,"insightId":"00a5758f-be49-4cf6-9927-748945d36822","activityUnion":{"commentActivity":{"socialMetadata":{"reactionTypeCounts":[],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:comment:(activity:7202293031339753472,7202318947818381313)","threadUrn":"urn:li:activity:7202293031339753472","reactionsCount":0,"commentsCount":0,"canComment":true},"commentary":{"attributes":[],"text":"So well deserved Licia! Wishing you all the best."},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:activity:7202293031339753472"}}},{"createdAt":1710864480000,"insightId":"c4b8df60-08bd-4e94-bc98-be28bab26041","activityUnion":{"commentActivity":{"socialMetadata":{"reactionTypeCounts":[],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:comment:(ugcPost:7175560471104622594,7175885794681749504)","threadUrn":"urn:li:ugcPost:7175560471104622594","reactionsCount":0,"commentsCount":0,"canComment":true},"commentary":{"attributes":[],"text":"Congrats Roberto"},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:ugcPost:7175560471104622594"}}}]}